IL-12 GEMys

Phase 1

NNational Cancer Institute (NCI)

IL-12 GEMys is one of 6 therapeutic programs targeting Solid Tumor Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Solid Tumor MalignanciesNot yet recruiting

Solid Tumor MalignanciesPhase 1

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Solid Tumor Malignancies

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

3 2

Opdivo

Bristol-Myers Squibb

Phase 3

2 3

Fludara

Sanofi

Phase 1

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 1

5 5

Erbitux

IImclone

Phase 1

1 6

IL-12 GEMys

NNational Cancer Institute (NCI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Not yet recruiting

Solid Tumor Malignancies

NCT07672483

Clinical

Trials by Indication[1]

Solid Tumor Malignancies1 trial

Phase I Trial of IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT07672483·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IL-12 GEMys. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for IL-12 GEMys. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

IL-12 GEMys

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Solid Tumor Malignancies1 trial

References

Drug Info

Quick Facts

Related News